Edition:
United States

GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

37.47USD
7 Dec 2016
Change (% chg)

$-0.22 (-0.57%)
Prev Close
$37.69
Open
$37.47
Day's High
$37.49
Day's Low
$37.20
Volume
2,853,432
Avg. Vol
3,261,560
52-wk High
$45.58
52-wk Low
$37.20

Latest Key Developments (Source: Significant Developments)

GlaxoSmithKline says vaccines chairman Slaoui to retire in 2017
Tuesday, 14 Jun 2016 05:58am EDT 

Glaxosmithkline Plc : Moncef Slaoui, Chairman, Vaccines, has indicated to board his intention to retire from company in 2017 . Board supports Dr Slaoui's decision and has agreed he will retire on June 30 2017 .Slaoui will remain member of board until March 31 2017; from April 1 2017 until retirement will serve as an advisor to GSK.  Full Article

ViiV Healthcare says FDA approves sNDA for dolutegravir
Friday, 10 Jun 2016 09:10am EDT 

Viiv Healthcare Ltd : ViiV Healthcare announces FDA approval to lower weight limit for dolutegravir in children and adolescents living with HIV . FDA has approved a supplemental new drug application for dolutegravir 10mg and 25mg oral tablets, reducing weight limit . FDA approved supplemental new drug application for dolutegravir oral tablets, reducing weight limit to at least 30kg Further company coverage: [IPO-VIHL.L] (Bengaluru Newsroom: +91 80 6749 1136).  Full Article

GSK rheumatoid arthritis, SLE drug meets late stage study goal
Wednesday, 8 Jun 2016 05:38am EDT 

Glaxosmithkline Plc :New phase III data shows greater treatment response with GSK's Benlysta (Belimumab) versus placebo in patients with highly active SLE.  Full Article

Mylan launches generic rythmol sustained-release capsules
Thursday, 2 Jun 2016 07:00am EDT 

Mylan NV : Mylan launches generic rythmol sustained-release capsules .U.S. launch of propafenone hydrochloride extended-release capsules USP, 225 mg, 325 mg, 425 mg, a generic version of glaxosmithkline's Rythmol Sr.  Full Article

GlaxoSmithkline accelerates filing of COPD triple-therapy drug
Thursday, 2 Jun 2016 02:00am EDT 

Glaxosmithkline Plc : Regulatory update on us filing plans for closed triple combination therapy ff/umec/vi in patients with copd .Acceleration of filing of us new drug application now expected by end of 2016.  Full Article

Regulus expands clinical trial collaboration with GSK
Wednesday, 1 Jun 2016 08:00am EDT 

Regulus Therapeutics Inc : Ongoing phase ii rg-101 and oral gsk2878175 combination study on track to report interim results by year-end .Regulus expands clinical trial collaboration with gsk.  Full Article

Fitch downgrades GSK to 'A' with stable outlook
Friday, 27 May 2016 11:38am EDT 

Fitch: Fitch downgrades GSK to 'A', outlook stable . Downgrade reflects fitch's view of a weakening business risk profile for GlaxoSmithKline PLC . Has also downgraded senior unsecured rating for debt issued under Glaxosmithkline Capital PLC to 'A' from 'A+' .Has assigned a senior unsecured rating of 'A' to debt issued by GlaxoSmithKline Capital Inc.  Full Article

GlaxoSmithKline appoints Vivienne Cox to board
Friday, 27 May 2016 09:56am EDT 

Glaxosmithkline Plc : Board and committee changes .Dr Vivienne Cox, CBE, has been appointed to board of company as a non-executive director with effect from 1 July 2016.  Full Article

GSK says gene therapy for immune disorder meets main goal
Wednesday, 25 May 2016 05:09am EDT 

Glaxosmithkline Plc : Key efficacy endpoint for analysis was survival. All 18 patients were alive after a median follow-up of 6.9 years at data cut on 8th may 2014 . Immune reconstitution was observed from six months post-treatment for majority of patients, and was sustained over .Overall safety findings in study were in line with expectations.  Full Article

Glaxosmithkline and Innoviva report positive headline results in Salford Lung study
Tuesday, 24 May 2016 05:54am EDT 

Glaxosmithkline Plc : Co and Innoviva announced positive headline results from innovative salford lung study in chronic obstructive pulmonary disease . Study showed that relvar ® ellipta ® 100/25mcg achieved a superior reduction in exacerbations versus usual care, in patients with copd . Analyses remain ongoing and will be subject of future publications and presentations . Second salford lung study is currently being conducted in asthma patients, with results expected in 2017 .For primary effectiveness analysis, in patients treated there was statistically significant reduction in rate of moderate or severe exacerbations.  Full Article

Photo

Exclusive: Novartis in talks to sell some central nervous system drugs - sources

ZURICH Novartis is in talks about the sale of some older neuroscience drugs, people close to the matter said, as the Swiss drugmaker clears the decks to concentrate on promising new medicines it hopes will help to restore sales growth.